Madrigal Pharmaceuticals, Inc. (MDGL) News

Madrigal Pharmaceuticals, Inc. (MDGL): $276.48

-3.31 (-1.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter MDGL News Items

MDGL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MDGL News Highlights

  • For MDGL, its 30 day story count is now at 3.
  • Over the past 17 days, the trend for MDGL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • ICPT, BODY and DRUG are the most mentioned tickers in articles about MDGL.

Latest MDGL News From Around the Web

Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit

With the business potentially at an important milestone, we thought we'd take a closer look at Madrigal...

Yahoo | January 30, 2023

Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA

Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.

Yahoo | January 20, 2023

Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why

Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.

Yahoo | January 13, 2023

7 Long-Term Stocks to Buy and Hold Forever

Now may be the time to scoop up high-quality names that continue to trade at very favorable valuations.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | January 10, 2023

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint resultsThese data will be presented at the NASH-TAG Conference on Friday January 6th, 2023 CONSHOHOCKEN, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage

Yahoo | January 6, 2023

Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal

Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.

Yahoo | January 4, 2023

Why These 7 Healthcare Stocks Could Soar in 2023

These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.

Muslim Farooque on InvestorPlace | January 2, 2023

This Stock That Tripled in 2022 Could Rocket Even Higher in 2023

Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.

Yahoo | December 26, 2022

Why Madrigal Pharmaceuticals Was a Top Stock This Week

This week was going down as one to remember for Madrigal Pharmaceuticals (NASDAQ: MDGL). According to data compiled by S&P Global Market Intelligence, the biotech's shares were an eye-watering 350% higher week to date, as of Thursday's market close. Biotechs tend to pop like that when they report excellent clinical-trial results; such was the case with Madrigal.

Yahoo | December 23, 2022

7 Drug Stocks That Will Soar in 2023

These drug stocks to buy look poised to generate huge profits for investors., both in 2023 and in subsequent years.

Larry Ramer on InvestorPlace | December 22, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.792 seconds.